In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
FAQs
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:

Start-Up Previews (01/01)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Skin Repair, features profiles of Artecel Sciences Inc., Niadyne Inc., Reconstructive Technologies Inc. and Renovo Ltd..Plus these selected Start-ups across Health Care: Aptilon Health Inc., Neuronyx Inc. , Oxxon Pharmaccines Ltd. and Third Millennium Inc.

You may also be interested in...



Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint

The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.

Regulatory Science Tools For Phantoms, Lab Methods Added To US FDA Catalog

The regulatory tools are for use in medical device development.

FDA To Hold Postponed 3-Day Pediatric Device Workshop In February

The US agency plans to hold a virtual workshop that will use breakout sessions to get stakeholder feedback on specific hurdles preventing more pediatric devices coming to market.

Table

View full table

Related Companies

Tags:
UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By